N-(4-(hydrazinecarbonyl)pyridin-2-yl)acetamide | 58481-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-(hydrazinecarbonyl)pyridin-2-yl)acetamide
• 英文别名: 2-Acetylaminoisonicotinsaeurehydrazid；2-acetylaminopyridine-4-hydrazide；N-[4-(hydrazinecarbonyl)pyridin-2-yl]acetamide
• CAS: 58481-02-0
• 化学式: C₈H₁₀N₄O₂
• 分子量: 194.193
• InChiKey: WJESGJRNBIPQFA-UHFFFAOYSA-N

物化性质

• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  97.1
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-(4-(hydrazinecarbonyl)pyridin-2-yl)acetamide 生成 4-azidocarbonyl-2-acetylaminopyridine
  参考文献：
  名称：

  Substituted 2-aminopyridines as inhibitors of nitric oxide synthase

  摘要：

  公式（I）中的2-氨基吡啶化合物及其药用盐已被发现在治疗一氧化氮合酶介导的疾病和紊乱中具有用处。

  公开号：

  US05972975A1
• 作为产物：
  描述：

  2-氨基异烟酸甲酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 54.0h， 生成 N-(4-(hydrazinecarbonyl)pyridin-2-yl)acetamide
  参考文献：
  名称：

  Structure-based optimization of oxadiazole-based GSK-3 inhibitors

  摘要：

  Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases beta-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3 alpha and beta, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3 alpha and 17 nM for GSK-3 beta. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3 alpha over GSK-3 beta, with an IC50 of 35 nM for GSK-3 alpha. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.006

文献信息

• ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS
  申请人：Pharma 2100

  公开号：EP2068873A2

  公开（公告）日：2009-06-17
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20170362234A1

  公开（公告）日：2017-12-21

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• US5972975A
  申请人：——

  公开号：US5972975A

  公开（公告）日：1999-10-26
• [EN] SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE<br/>[FR] 2-AMINOPYRIDINES SUBSTITUEES UTILISEES COMME INHIBITEURS DE SYNTHASE D'OXYDE D'AZOTE
  申请人：MERCK & CO., INC.

  公开号：WO1996018616A1

  公开（公告）日：1996-06-20

  (EN) Substituted 2-aminopyridine compounds and pharmaceutically acceptable salts which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders.(FR) Composés de 2-aminopyridine substituée et leurs sels viables sur le plan pharmaceutique pouvant être utilisés dans le traitement de maladies et de troubles dus à la synthase d'oxyde d'azote.
• [EN] ISONIAZID MEDIATED HEALING OF WOUNDS AND ULCERS<br/>[FR] GUÉRISON DES BLESSURES ET DES ULCÈRES SOUS LA MÉDIATION DE L'ISONIAZIDE
  申请人：PHARMA 2100

  公开号：WO2008031440A2

  公开（公告）日：2008-03-20

  [EN] The invention relates to the use of a compound(s) selected from isoniazid and isoniazid analogs of formula Ia, wherein R is -C(O)NHNH₂, -C(O)NHNHC_1-6 alkyl, -C(O)NHN=C₁-₆ alkenyl, -C(O)NHNHC_2-6 alkenyl, -C(O)NHC_1-6 alkyl, -C(O)NHC_2-6 alkenyl, -C(O)NHNHC(O)C_1-6alkyl, -NHC(O)C_1-6 alkyl, -NHC(O)C_1-6 alkenyl, -NHC(O)NH₂, -NHC(O)NHC_1-6 alkyl, -NHC(O)NHC_2-6 alkenyl, or -COOH, and wherein formula (Ia) optionally is further substituted with one or more substituents; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the preparation of a pharmaceutical composition for treating a condition selected from the group consisting of cutaneous lesions, wounds, ulcers and infarcts in a tissue area with compromised vascularisation, in an animal, such as a human subject. The compound is preferably isoniazid, or pharmaceutical acceptable salts, solvates or prodrugs thereof, and the conditions to be treated is for example selected from the group consisting of pressure ulcers, diabetic ulcers, arterial ulcers and anastomotic ulcers. The invention furthermore relates to a method of treating a condition selected from wounds, ulcers or infarcts in a tissue area with compromised vascularisation in an animal, such as a human subject.
  [FR] La présente invention concerne l'utilisation d'un ou de plusieurs composés choisis parmi l'isoniazide et des analogues de l'isoniazide de formule (Ia), dans laquelle R est -C(O)NHNH₂, -C(O)NHNH-alkyle en C_1-6, -C(O)NHN=alkényle en C₁-₆, -C(O)NHNH-alkényle en C_2-6, -C(O)NH-alkyle en C_1-6, -C(O)NH-alkényle en C_2-6, -C(O)NHNHC(O)-alkyle en C_1-6, -NHC(O)-alkyle en C_1-6, -NHC(O)-alkényle en C_1-6, -NHC(O)NH₂, -NHC(O)NH-alkyle en C_1-6, -NHC(O)NH-alkényle en C_2-6 ou -COOH, la formule (Ia) étant en outre facultativement substituée avec un ou plusieurs substituants ; ou leurs sels, solvates ou promédicaments pharmaceutiquement acceptables, pour la préparation d'une composition pharmaceutique destinée au traitement d'une affection choisie dans le groupe comprenant les lésions cutanées, les blessures, les ulcères et les infarctus dans une zone tissulaire à vascularisation altérée, chez un animal tel qu'un sujet humain. De préférence, le composé est l'isoniazide ou ses sels, solvates ou promédicaments pharmaceutiquement acceptables et l'affection à traiter est choisie par exemple dans le groupe comprenant les ulcères de décubitus, les ulcères diabétiques, les ulcères artériels et les ulcères peptiques. L'invention concerne en outre un procédé de traitement d'une affection choisie parmi les blessures, les ulcères et les infarctus dans une zone tissulaire à vascularisation altérée chez un animal tel qu'un sujet humain.